Brown Brothers Harriman & Co. Sells 441 Shares of GSK plc (NYSE:GSK)

Brown Brothers Harriman & Co. trimmed its stake in GSK plc (NYSE:GSK) by 5.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,408 shares of the pharmaceutical company’s stock after selling 441 shares during the period. Brown Brothers Harriman & Co.’s holdings in GSK were worth $285,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in GSK. Dimensional Fund Advisors LP raised its position in shares of GSK by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock worth $65,883,000 after acquiring an additional 18,585 shares in the last quarter. Trexquant Investment LP increased its position in GSK by 1,710.6% during the 4th quarter. Trexquant Investment LP now owns 121,746 shares of the pharmaceutical company’s stock valued at $4,512,000 after buying an additional 115,022 shares in the last quarter. Assetmark Inc. increased its position in GSK by 1,598.7% during the 4th quarter. Assetmark Inc. now owns 2,582 shares of the pharmaceutical company’s stock valued at $96,000 after buying an additional 2,430 shares in the last quarter. Franklin Resources Inc. increased its position in GSK by 0.9% during the 4th quarter. Franklin Resources Inc. now owns 64,336 shares of the pharmaceutical company’s stock valued at $2,451,000 after buying an additional 602 shares in the last quarter. Finally, JPL Wealth Management LLC acquired a new position in GSK during the 4th quarter valued at about $1,129,000. 15.74% of the stock is owned by institutional investors.

GSK Stock Down 0.3 %

GSK stock opened at $42.43 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The business’s 50-day simple moving average is $41.30 and its two-hundred day simple moving average is $41.71. The company has a market cap of $87.94 billion, a PE ratio of 15.37, a PEG ratio of 1.41 and a beta of 0.66. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. Equities analysts anticipate that GSK plc will post 4.15 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a $0.3843 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.62%. GSK’s dividend payout ratio is presently 54.71%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. The Goldman Sachs Group assumed coverage on GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Citigroup raised GSK to a “strong-buy” rating in a research report on Monday, June 24th. Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Finally, Berenberg Bank raised GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Four analysts have rated the stock with a hold rating, two have given a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.